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Abstract: An unexpected increase in weight gain has recently been reported in the course of integrase
strand transfer inhibitors (INSTI) treatment. The possibility of this effect in people who are perinatally
infected with HIV (PHIV) and thus exposed to lifelong therapy needs to be explored. This is a
retrospective multicenter case-control study. Adults with PHIV followed between 2010 and 2019 in
two outpatient services in Northern Italy were included if they had at least two weight measures in
two successive years of observation. Patients were considered as cases if they were switched to INSTI
(INSTI group), or controls if they were never exposed to INSTI (non-INSTI group). The date of the
switch in cases was considered to be the baseline (T0), while it was randomly selected in controls.
Mixed effect models were used to assess the weight changes in INSTI and non-INSTI groups. A total
of 66 participants, 50.0% women, 92.4% Caucasian, were included. Median follow-up was 9 years
(range 2–10): 4 years (range 1–8) before and 3 (range 1–9) after-T0. Mean age at the last study visit
was 27.3 (±4.8) years, and mean CD4+ T-cells were 820.8 (±323.6) cells/mm3. Forty-five patients
were switched to INSTI during the study, while 21 remained in the non-INSTI group. The INSTI
group experienced a mean increase (pre-post T0) in bodyweight of 0.28 kg/year (95% CI − 0.29; 0.85,
p = 0.338), while in the non-INSTI group, the mean increase was 0.36 kg/year (95% CI − 0.47; 1.20,
p = 0.391), without a significant difference between groups (p for interaction between time and
treatment regimen = 0.868). Among patients on INSTI, the weight gain after T0 was higher than
pre-T0, amounting to +0.28 kg/year (95% CI − 0.29; 0.85), although this difference did not reach
significance (p = 0.337). PHIV switched to an INSTI-based regimen did not experience an excessive
weight gain compared to those who were treated with a non-INSTI based regimen in our cohort.
Keywords: integrase strand transfer inhibitor; weight gain; HIV metabolic complication; perinatal
HIV infection
1. Introduction
Several recent studies have highlighted an unexpected adverse effect of new antiretroviral drugs,
namely an increase in weight gain among people living with HIV (PLWHIV). Multiple drugs have
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been blamed to be a possible trigger of this side effect [1,2], and among anchor drugs, integrase
strand transfer inhibitors (INSTIs) seem to be those with the highest impact on weight [3–6]. The
weight gain seems higher in naïve, black, female people, with lower baseline weight and a higher
pre-treatment HIV-RNA load [1–5]. On the other hand, a weight increase has also been observed after
switching strategies in people with virological suppression initiating INSTIs [7–9]. The reasons for
weight increase as well as the metabolic and cardiovascular impact of the phenomenon remain to be
clarified. An excessive weight gain might be especially problematic especially in people infected with
HIV perinatally (PHIV), as they are characterized by a pro-inflammatory state [10,11], accelerated
ageing [12,13], high prevalence of dyslipidemia [14], and abnormal body fat distribution [15], in a
general picture of “metabolic frailty” [16]. In addition, adolescents living with HIV experience multiple
forms of stigma, which can further compromise their self-image and weight gain would be even more
relevant for them [17].
This population is, by definition, exposed by birth until death to HIV action and, consequently,
to lifelong antiretroviral treatment (ART). For these reasons, ART tolerability and cardiovascular safety,
as well as any impact on growth, are of particular importance in this setting, not only in the short term
after ART initiation, but also after many decades of exposure. However, PHIV are poorly represented
in clinical trials and, in many contexts, their ART and switching strategies, are guided by observational
studies alone. The possibility of treating them with an INSTI-based regimen is appealing. In fact,
it allows overcoming the resistance mutations accumulated in past years of suboptimal ART, to which
PHIV have almost invariably been exposed in the early ART era, often limiting possible therapeutic
options [18]. Moreover, INSTIs provide the opportunity of reducing the metabolic effects of protease
inhibitors (PIs) and older drugs on blood lipids and insulin resistance [16,19–22] and offer the option
of fewer drug and single tablet regimens, an important aspect for improving the adherence in children
and adolescents living with HIV [23]. On the other hand, the consequences of possible metabolic effects
of these drugs should also be considered, if there are any. In this observational study, we analyse
weight changes over 10 years of observation in adults and adolescents, all perinatally infected with
HIV, with the aim of evaluating if switching to INSTI has an impact on weight.
2. Methods
This is a retrospective, observational, multicentre study, conducted in two referral AIDS centres
following vertically HIV-infected children and adolescents in Northern Italy: Policlinico S. Martino
Hospital in Genoa and Paediatric Infectious Disease Unit, ASST Fatebenefratelli-Sacco, in Milan. Data
for Policlinico S. Martino were retrieved from MedInfo, an online database for anonymous and automatic
data collection [24]. Data from the Paediatric Infectious Disease Unit, ASST Fatebenefratelli-Sacco, were
retrieved by clinical chart revision. One weight measure per year, or the mean of the weight measures
(when more than one weight per year was available), was registered for each year of observation. Data
were afterwards merged in a single file for the analysis. All PHIV >18 years old were included in
the study if they had at least two weight measures in different years of follow up. Weight measures
were retrospectively retrieved for each patient, starting from the first available measure after 18 years
of age for males and 16 years for females, to avoid ambiguity related to weight increase as a result
of physiological growing [25,26]. We hypothesized that patients switching to or adding an INSTI to
ART (INSTI group) would experience greater increases in weight compared to those who remained on
non-INSTI ART (non-INSTI group). The criteria for the INSTI group included PHIV (1) who switched
from non-INSTI ART, which could have included any nucleoside reverse transcriptase inhibitor (NRTI)
backbone along with either adding a non-nucleoside reverse transcriptase inhibitor (NNRTI), protease
inhibitor (PI), or entry inhibitor to an INSTI, or adding an INSTI to ongoing ART; (2) at least two weight
measures available, one before and one 12 months after the switch and (3) remained on INSTI drugs
for at least 12 months following the switch/addition. Patients who performed intra-class switches from
one INSTI to another were always considered as part of the INSTI group until the last available follow
up or INSTI discontinuation. Criteria for the control (non-INSTI) group included PHIV treated with
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any drug regimens not including INSTIs and having at least two weight measures. The change of
one or more component of the antiretroviral regimen during the follow up did not lead to exclusion
from the study in either group. People with missing data or who did not satisfy the above-mentioned
criteria were excluded. Pregnant women were excluded from both groups as well.
All data were collected from January 2010 to December 2019. All patients followed in both
Policlinico S. Martino Hospital and ASST Fatebenefratelli-Sacco signed an informed consent form
in which they agreed to the use of their clinical data in an anonymous form for scientific purposes.
The use of the Ligurian HIV Network database for scientific purposes was approved by the Ligurian
Ethics Committee (P.R. 2/2013, Date of approval 28 August 2013). The study has been performed
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later
amendments, as well as in accordance with Italian national laws.
3. Statistical Methods
For clinical and demographic characteristics, descriptive statistics were used, such as mean ±
standard deviation (SD), median (range), and frequencies (percentage). Patients’ characteristics in
INSTI and non-INSTI groups were compared by chi-square test for categorical variables and Student’s
t-test for continuous variables. For the INSTI group, the date of the switch was considered as baseline
(T0). For the non-INSTI group, which never performed the switch to INSTIs, based on the study
definition, it was assumed that the weight change was constant over the study period. Therefore,
T0 was randomly assigned. Furthermore, the two groups have been verified to have a comparable
follow-up. Mixed effects models were used to assess weight change per year pre- and post- T0, and to
compare the post-T0 weight change between the INSTI and non-INSTI group. Models were adjusted
for age and weight at baseline and sex. An interaction term between time and treatment regimen was
used to assess the effect of the switch to an INSTI regimen on weight change. Additionally, a linear
regression model was applied to evaluate the association between birth weight and last available
body mass index (BMI) in the study population. SAS 9.3 (Institute Inc., Cary, NC, USA) was used for
the computation.
4. Results
4.1. Weight Gain in the Whole Study Population
Seventy-eight patients were considered for the present study, of whom twelve were excluded for
insufficient weight measures. The remaining 66 patients were included. They had a median follow-up
of 9 years (range 2–10 years): 4 years (range 1–8) before-T0 and 3 years (range 1–9) after-T0. Mean age
at the last study visit was 26.7 (SD ± 4.8) years, and the mean CD4+ T-cell count was 820.8 (SD ± 323.6)
cells/mm3 (Table 1). None of the study participants were in treatment with an INSTI-regimen at the
first observation. A mixed effect model adjusted for sex, weight and age at baseline showed a pre-T0
weight gain of +0.47 kg/year (95% CI − 0.14; 0.80) and a post-T0 weight gain of +0.77 kg/year (95% CI
− 0.44; 1.10) (p = 0.006 and p < 0.0001, respectively), without evidence of a significant change in the
rate of weight gain post-T0 (0.30 kg/year [95% CI − 0.16; 0.77], p = 0.200).
The analysis of weight change between pre- and post-T0 by gender showed a slightly increased
rate of weight gain post-T0 in female patients (+0.46 kg/year (95% CI − 0.16;1.07, p = 0.141), while a
trend was not seen in male patients (+0.15 kg/year (95% CI − 0.54; 0.84, p = 0.660), Table 2. The birth
weight did not show any correlation with the last available BMI in the study population (p = 0.927).
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Table 1. Baseline demographic and clinical characteristics for the 66 patients analyzed.
Variables All Patients INSTI Group Non-INSTI Group p-Value
Number of patients (%) 66 (100) 45 (68.18) 21 (31.82)
Mean Age (±SD), years 26.67 (±4.79) 26.53 (±4.79) 26.95 (±4.90) 0.853
Male Gender (%) 33 (50.00) 23 (51.11) 10 (47.62) 0.792
Mean weight (±SD), kg 58.65 (12.51) 59.63 (13.66) 56.56 (9.54) 0.711
Caucasian ethnicity 61 (92.42) 42 (93.33) 19 (90.48) 0.683
Mean Born weight (±SD), grams 2863.40 (±725.64)N = 47
2845.15 (±636.62)
N = 33
2906.43 (±928.83)
N = 14 0.972
Mean CD4+T-cell count,
cells/mm3 (at last clinical
evaluation)
817.68 (±335.21)
N = 65
770.98 (±348.18)
N = 44 915.52 (±289.94) 0.059
INSTI: integrase strand transfer inhibitor; SD: standard deviation.
Table 2. Annual rate of weight change pre and post the time of the switch (T0) to integrase strand
transfer inhibitor (INSTI). For the non-INSTI group T0 was randomly assigned, assuming that the
weight change was constant over the study period.
Weight Change in
kg/Year
All Patients *
(N = 66)
Female **
(N = 33)
Male **
(N = 33)
Pre-T0
(p-value)
+0.47 (0.14–0.77)
(0.006)
+0.52 (0.08–0.95)
(0.020)
+0.42 (−0.06–0.91)
(0.126)
Post-T0
(p-value)
+0.77 (0.44–1.10)
(<0.0001)
+0.97 (0.54–1.41)
(<0.0001)
+0.57 (0.09–1.06)
(0.086)
Pre-post Difference
(p-value)
+0.30 (−0.16–0.77)
(0.200)
+0.46 (−0.16–1.07)
(0.141)
+0.15 (−0.54–0.84)
(0.660)
* Adjusted for age, sex and weight at baseline; ** adjusted for age and weight at baseline.
4.2. Comparison of Weight Change in INSTI vs. Non-INSTI-Treated Patients
Among the patients included in the study, 45 switched to an INSTI-based regimen (INSTI group),
while 21 were never treated with an ART regimen including INSTI (non-INSTI group). The baseline
characteristics of the two groups are shown in Table 1.
The INSTI group experienced a mean increase (pre-post T0) in body weight of 0.28 kg/year (95% CI
− 0.29; 0.85, p = 0.338), while, in the non-INSTI group, the mean increase was 0.36 kg/year (95% CI −
0.47; 1.20, p = 0.391), Table 2. Patients on the INSTI regimen gained slightly less weight compared to
the non-INSTI group after T0 (−0.09 kg/year), but this difference was not significant (p for interaction
between time and treatment regimen = 0.868, Figure 1). Six patients had a BMI > 30 and were thus
considered obese at the end of the study: three in the INSTI and three in the non-INSTI group.
Analyzing the change in weight by sex, we noticed that male patients on the INSTI regimen
seemed to gain slightly less weight compared male patients on a non-INSTI regimen (−0.26 kg/year),
while the same trend was not seen in female patients (+0.10 kg/year). Both differences were not
significant (p for interaction between time and treatment regimen = 0.733 and 0.879, respectively).
We then adjusted the model for birth weight as well. The model retained 47 patients with
available birth weight values (14 never switched, 33 switched to INSTI). Patients who switched to
an INSTI regimen seemed to gain more weight compared to those who remained in a non-INSTI
regimen (+0.42 kg/year), but this weight increase was not significant (p for interaction between time
and treatment regimen = 0.522).
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with or without integrase strand transfer inhibitors (INSTI)-based antiretroviral regimens.
4.3. Trend of Weight in INSTI Treated Patients
Finally, w erform d a sensitivity analysis only including 45 INSTI-treated patie ts (Table 3).
Table 3. Annual rate of weight change pre and post switch to integrase strand transfer inhibitors
(INSTI), according to INSTI regimen. For the non-INSTI group the date of the switch (T0) was randomly
assigned, assuming that the weight change was constant over the study period.
Weight Change in kg/Year Non-INSTI Group *(N = 21)
INSTI Group *
(N = 45)
Pre-T0
(p-value)
+0.38 (−0.21–0.97)
(0.204)
+0.51 (0.11–0.91)
(0.014)
Post- T0
(p-value)
+0.74 (0.15–1.34)
(<.0001)
+0.79 (0.38–1.19)
(0.0002)
Pre-post Difference
(p-value)
+0.36 (−0.47–1.20)
(0.391)
+0.28 (−0.29–0.85)
(0.338)
* Adjusted for age, sex and weight at baseline.
These patients seemed to gain slightly more weight after switching to an INSTI regimen compared
to the time before the switch (+0.28 kg/year. 95% CI − 0.29; 0.85), but this weight gain was not
significant (p = 0.337).
Furthermore, limiting the observation to only at the time following the switch, we did not find a
substantial change in weight gain in patients switched for virologic failure (HIV RNA >50 copies/mL
the time of INSTI initiation, N = 12) compared to people who switched for other reasons (−0.59 kg/year,
[95% CI − 1.77; 0.59], p = 0.318).
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5. Discussion
In this study, we evaluated weight changes over a 10-year period in young adult PHIVs and found
that although all patients experienced an increase in weight during the observation, this increase was
not linked to INSTI use. A certain rate of weight gain over time, unrelated to ART, could be expected,
as even in the general population, young adult men and women have been found to gain 0.55 and
0.52 kg per year [26], respectively, with those who had a rapid and early weight gain during young
adulthood being the most likely to be at risk of obesity-related conditions [27]. However, in people
living with HIV infection during adulthood, a greater than expected increase of weight was noticed in
cases treated with both first line [3,5,28] and switching strategies [7,29] with INSTIs. The reasons for the
lack of this same effect among young PHIV might be due to the different characteristics of participants
enrolled in this study compared to other contexts. For example, black people were poorly represented,
and they seem to be particularly at risk of weight increase in the course of INSTIs [5,28,30]. Moreover,
in our study, participants were younger compared to those enrolled in previous studies [7–9], and older
age is a recognized risk factor for fat and weight increase, at least until elderly age [8,31]. However,
studying the weight change at a younger age is still very important, since at as early as 18 years of age,
high body mass index can be predictive of increased risk for all-cause mortality and of major ischemic
heart disease at old age [32]. Moreover, previous studies highlighted that children infected with HIV
have adverse cardiac risk profiles compared with age-paired uninfected controls, presumably as a
consequence of both chronic inflammation and exposure to antiretroviral therapy [33,34]. On the other
hand, although almost all studies found a weight increase under ART, not all switch studies confirmed
the linkage with INSTI use [1,9,35], whose effect in the switch strategies might be less incisive than
what was previously reported in naïve patients. Additionally, the weight gain is expected, especially
with some INSTIs, such as dolutegravir and bictegravir, and not for all INSTIs [3,5,7,28], with risks
differing according to drug combinations [5,36]. However, in our study, due to the small sample size,
we did not have the opportunity of sub-group analyses of different INSTIs and different backbones,
and this could clearly constitute a limitation. Moreover, we did not find a significant difference in
weight increase between the INSTI and non-INSTI groups, but it is possible that the sample size was
too small for the data to be significant. In fact, the interaction analysis that we used to investigate the
effect modification by the INSTI regimen on the association between time and weight would have
required a larger sample size, and the low number of participants in the two groups of the present
study may have significantly affected the results. However, the mean increase per year was similar in
the two groups of patients, and also to that reported in the general population [27]. Finally, the results
that we found in this study in Italy might not be representative of other geographical and cultural
contexts where dietary habits as well as attitudes towards physical activity might be very different.
Moreover, data on personal choices, health or sociopsychological conditions influencing weight loss
or gain were not recorded, limiting the generalizability of these results. With these limitations, our
study analyzes an issue that is very important for the future management of PHIV, because many
young adolescents and children born with HIV infections now have the possibility to grow old, thanks
to the high efficacy of modern ART and drug policies that facilitate the access and supply of drugs,
even in limited resource settings [37]. On the contrary, in the past, due to high HIV-related mortality
in childhood [38], many PHIVs did not have the chance to reach adulthood and, therefore, there are
no historical data on the impact of long-term treatment and on how it is best to treat them over time.
This work might have a bearing on potentially greater burden HIV settings, such as Africa, and also in
industrialized countries, where mother to child transmission has not been eliminated yet [39].
In conclusion, the weight trajectories that we described in young adult PHIV were similar between
INSTI and non-INSTI-treated patients. These results might suggest that INSTI can be used in young
adults, who have been perinatally infected with HIV, without expecting excessive weight increase.
In the future, it will be increasingly important to join data in multicenter cohort studies in order to
confirm these results.
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